Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation phase 1 study of LY2599666 and solanezumab in healthy volunteers and participants with Alzheimer's disease
jRCT2080223114Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY2599666 and solanezumab in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease (6 arms), sponsored by Eli Lilly and Company. Primary endpoints: Safety and tolerability of LY2599666 and solanezumab and Pharmacokinetics of LY2599666 and solanezumab. Started Feb 2016; status: recruiting.
02
Drugs
LY2599666solanezumab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on jRCT2080223114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223114.